Microbiome Therapeutics Market Outlook 2031
The global microbiome therapeutics market size was USD 94.86 Million in 2022 and is projected to reach USD 1.45 Billion by 2031 register a substantial CAGR 35.42% during the forecast period, 2023-2031. attributed to the rising incidence of diseases owing to microbiota dysbiosis in the gut. The market growth is further attributed to a large amount of funding made for the development studies of various biological drugs.
The microbe with genetic material including fungi, protozoa, bacteria, and viruses that lives inside the gut of a human body is known as the microbiome. They are mostly present in the large intestine. The bacteria present in the microbiome help in the regulation of the immune system, digestion of food, and protection against disease-causing bacteria.
The good health of a person is associated with the gut microbiome. When the number of microorganisms including actinobacteria, bacteroidetes, and firmicute alters, it leads to arthritis, diabetes, gastrointestinal disorders, lung & respiratory disorders, and several other neurological disorders. The reduction of these microorganisms is caused due to unhealthy lifestyles, long-term usage of antibiotics that are of heavy dosage, and increasing age.
Infectious diseases and organisms such as ulcerative colitis and clostridium difficile get induced in the human body due to a decrease in the level of beneficial microbiota.
The COVID-19 pandemic outbreak had a positive impact on the microbiome therapeutics market due to its association with immunity and various respiratory diseases. As per the reports published by the Human Microbiome Journal named “Lung microbiome and COVID-19: Possible Link and Implications,” lung microbiome is expected to have an impact on the seriousness and sensitivity of the pandemic. It is also expected to play a vital role in the prompting of the immune response against this widespread of SARS-CoV-2 infection.
Microbiome Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Rise in prevalence of various diseases that are related to inactive lifestyle and growing number of the geriatric population are anticipated to fuel the market growth during the forecast period.
- Availability of strong pipelines for drugs in the developed regions is expected to drive the market expansion in the coming years.
- Increasing collaborations among several companies for the development and launch of drugs are key factors estimated to propel the market growth.
- Rigid & strict regulations imposed by the government and lack of thorough research are key restraining factors that are expected to hinder the market growth.
- Increasing initiatives taken by governments for raising funds in order to support research work presents a key factor projected to create profitable opportunities for the market expansion.
Scope of the Microbiome Therapeutics Market Report
The report on the global microbiome therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Microbiome Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Types (Microbiome Drugs and Fecal Microbial Transplant) and Applications (Diabetes, C. Difficile, Inflammatory Bowel Disease, Crohn’s Disease, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC.
|
Microbiome Therapeutics Market Segment Insights
Microbiome drugs is expected to grow at a rapid pace
On the basis of types, the global microbiome therapeutics market is bifurcated into microbiome drugs and fecal microbial transplant. The fecal microbial transplant segment is projected to hold a key market share in the coming years owing to wide recommendation of the therapeutic method by professionals after it was approved by the Investigational New Drug (IND) for biological therapy.
The fecal microbial transplant dominated the market in 2019 as it was the only available option for C. difficile therapeutics. However, the microbiome drugs segment is expected to grow at a rapid pace owing to the presence of product pipelines in phase 2 that are strong and considered to be effective drugs.
Crohn’s disease is estimated to expand at a fast growth rate
Based on applications, the market is segmented into diabetes, C. difficile, inflammatory bowel disease, Crohn’s disease, and others. The C. difficile segment accounted for a large revenue share of the market in 2019 and is projected to exhibit a high CAGR during the forecast period owing to the wide approval of fecal microbial transplant, the only treatment available for it. However, Crohn’s disease is estimated to expand at a fast growth rate in the coming years due to the high presence of drug pipelines for its treatment.
Asia Pacific is anticipated to expand at a considerable CAGR
In terms of regions, the global microbiome therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2019 and is expected to grow substantially during the targeted period attributed to the availability of a large number of patients and presence of a large number of health conscious population.
Moreover, the presence of advanced research facilities and increasing expenditures for healthcare in the region present another key aspects for the regional market expansion. On the other hand, the market of Asia Pacific is anticipated to expand at a considerable CAGR during the forecast period owing to the increasing stability of the economy, increasing awareness regarding therapeutics among professionals, and rise in the number of initiatives by national institutes for biological research in the region.
Segments
The global microbiome therapeutics market has been segmented on the basis of
Types
- Microbiome Drugs
- Fecal Microbial Transplant
Applications
- Diabetes
- C. Difficile
- Inflammatory Bowel Disease
- Crohn’s Disease
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- OpenBiome
- Seres Therapeutics
- Genome
- Enterome Bioscience
- Ritter Pharmaceuticals
- Second MaaT Pharma
- Rebiotix, Inc.
- MicroBiome Therapeutics LLC
Competitive Landscape
Key players competing in the global microbiome therapeutics market are OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
Some of the key players have received high funding for the development of pipelines for microbiome therapeutics. For example, nearly USD 160 million was invested by Seventure Partners for research in this field.